Ferring Pharmaceuticals announced today a new analysis of data from the Phase 3 ESTHER-1 trial showing that natural variations in anti-Müllerian hormone (AMH) levels during and between a woman's ...

Ferring’s novel human recombinant follicle stimulating hormone (human rFSH) Rekovelle has now been launched across the UK for use in controlled ovarian stimulation. Ferring’s novel human recombinant ...

SAINT-PREX, Switzerland--(BUSINESS WIRE)--Ferring Pharmaceuticals announced today that the filing for the Marketing Authorisation Application for REKOVELLE ® (follitropin delta) has been accepted for ...

SAINT-PREX, Switzerland — Ferring Pharmaceuticals announced today a new analysis * of data from the Phase 3 ESTHER-1 trial 1 showing that natural variations in anti-Müllerian hormone (AMH) levels ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. REKOVELLE is used in the treatment of infertility (reproduction ...

Ferring Announces Abstract of the First Prospective, Multi-National, Real-world Study of Rekovelle® (follitropin delta) at the Congress of the Pacific Society for Reproductive MedicineBack to video ...

If approved, REKOVELLE ® would be administered using an individualised dosing regimen according to a woman’s serum anti-Müllerian hormone (AMH) level and her body weight. AMH is a biomarker used to ...

· New study demonstrates that individualised dosing with Rekovelle ® (follitropin delta) was comparable to conventional dosing with follitropin alfa in terms of ongoing pregnancy rate in a broad Asian ...

SAINT-PREX, Switzerland–(BUSINESS WIRE)–Ferring Pharmaceuticals announced today that the European Commission ...

“With Ferring’s headquarters in Switzerland, we are particularly proud to announce the Swissmedic approval of Rekovelle, the first fertility medication to offer women a personalised approach, right ...

Ferring Pharmaceuticals is halting work on two trials of a phase 1 infertility candidate that together had enrolled 416 patients. The Celestial-1 and Celestial-2 trials, testing the pairing of ...

PROFILE is the first prospective, multi-national, observational, real-world study of Rekovelle in clinical practice, conducted in more than 940 women from 10 countries across Europe, North America and ...